OptimizeRx (NASDAQ: OPRX), a leading healthcare technology company that connects life science brands with patients and healthcare providers, announced it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility comprises a $25 million term loan and a $10 million revolving credit facility, which was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction.
The new credit facility provides OptimizeRx with additional capital to support its growth initiatives, including investments in its AI-driven platform and expansion of its digital marketing solutions. The company’s platform combines innovative tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver hyper-local engagement. By bridging the gap between healthcare provider and direct-to-consumer strategies, OptimizeRx aims to drive faster treatment decisions and improve patient outcomes.
This announcement is significant as it strengthens OptimizeRx’s balance sheet and provides financial flexibility to pursue strategic opportunities. The company has been at the forefront of transforming how life science companies connect with stakeholders, using privacy-safe, patient-centric technology. With this funding, OptimizeRx can accelerate the development and deployment of its platform, potentially increasing its market share in the competitive healthcare technology sector.
For more details, visit the full announcement at https://ibn.fm/G0Fj3. Information about OptimizeRx can be found at www.optimizerx.com.
The facility with Fifth Third Bank, a major financial institution, reflects confidence in OptimizeRx’s business model and growth prospects. As the healthcare industry increasingly adopts digital solutions, OptimizeRx is well-positioned to benefit from this trend. The company’s focus on AI and data-driven marketing aligns with broader industry shifts toward personalized medicine and value-based care.
OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies, and its technology is designed to make a meaningful impact by delivering life-changing therapies to the right patients at the right time. With the new credit facility, the company is poised to expand its reach and enhance its offerings, potentially leading to improved health outcomes and increased shareholder value.
